Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo
December 19 2017 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led
biopharmaceutical company focused on identifying, developing, and
commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology, today
announced that it has initiated a Phase 2 open-label clinical trial
of ATI-50002, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-50002
Topical) and an investigational drug, for the potential treatment
of non-segmental vitiligo of the face.
This trial will evaluate the safety, tolerability and
preliminary efficacy of ATI-50002 Topical applied twice daily in 24
adult subjects with non-segmental vitiligo of the face. This
24-week trial will be conducted at 3 investigational centers within
the United States.
“This trial is the first step in evaluating the potential
clinical benefit of ATI-50002 Solution in treating patients with
non-segmental vitiligo of the face,” said Dr. Stuart Shanler, Chief
Scientific Officer of Aclaris. “This is an important step forward
in understanding the clinical utility of our JAK program in
patients with vitiligo.”
About Vitiligo Vitiligo is an autoimmune
disease in which the pigment producing skin cells (melanocytes) are
progressively lost from the skin. As a result, pigment (melanin) is
absent and areas of skin appear to be lighter on various parts of
the body. The cause of vitiligo is unknown; however, an
autoimmune-mediated destruction of the pigment cells is currently
the most favored theory. Impacting one to two percent of the global
population, vitiligo is considered the most frequently occurring
depigmenting disorder. Irrespective of sex, race or age, the
condition is more prominently found in darker skinned individuals.
Its sufferers may experience reduced quality of life and
psychological distress. None of the currently available treatment
options are perceived to manage vitiligo adequately. There are
currently no FDA-approved medications for vitiligo that restore
pigmentation.
About Aclaris Therapeutics, Inc. Aclaris
Therapeutics, Inc. is a dermatologist-led biopharmaceutical
company focused on identifying, developing and commercializing
innovative and differentiated therapies to address significant
unmet needs in medical and aesthetic dermatology. Aclaris is
focused on large, underserved market segments with
no FDA-approved medications or where treatment gaps exist.
Aclaris is based in Malvern, Pennsylvania and more
information can be found by visiting the Aclaris website
at www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “may,” “plan,” “potential,” “will,” and
similar expressions, and are based on Aclaris’ current beliefs and
expectations. These forward-looking statements include expectations
regarding the commercial availability of ESKATA in the spring of
2018 and the expected market opportunity for ESKATA. These
statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such
statements. Risks and uncertainties that may cause actual results
to differ materially include Aclaris’ reliance on third parties
over which it may not always have full control and other risks and
uncertainties that are described in the Risk Factors section of
Aclaris’ Annual Report on Form 10-K for the year ended December 31,
2016, Aclaris’ Quarterly Report on Form 10-Q for the quarter ended
September 30, 2017, and other filings Aclaris makes with the U.S.
Securities and Exchange Commission from time to time. These
documents are available under the “Financial Information” section
of the Investors page of Aclaris’ website at
http://www.aclaristx.com. Any forward-looking statements speak only
as of the date of this press release and are based on information
available to Aclaris as of the date of this release, and Aclaris
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact: Aclaris Contact Michael Tung, M.D. Vice President /
Investor Relations 484-329-2140 mtung@aclaristx.com Media
Contact Mariann Caprino TogoRun 917-242-1087
M.Caprino@togorun.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024